pyruvate dehydrogenase kinase/lactate axis: a therapeutic target for neovascular age-related macular degeneration identified by metabolomics

Neovascular age-related macular degeneration (namd) is the leading cause of blindness in aging populations. here, we applied metabolomics to human sera of patients with namd during an active (exudative) phase of the pathology and found higher lactate levels and a shift in the lipoprotein profile (increased vldl-ldl/hdl ratio). similar metabolomics changes were detected in the sera of mice subjected to laser-induced choroidal neovascularization (cnv). in this experimental model, we provide evidence for two sites of lactate production: first, a local one in the injured eye, and second a systemic site associated with the recruitment of bone marrow–derived inflammatory cells. mechanistically, lactate promotes the angiogenic response and m2-like macrophage accumulation in the eyes. the therapeutic potential of our findings is demonstrated by the pharmacological control of lactate levels through pyruvate dehydrogenase kinase (pdk) inhibition by dichloroacetic acid (dca). mice treated with dca exhibited normalized lactate levels and lipoprotein profiles, and inhibited cnv formation. collectively, our findings implicate the key role of the pdk/lactate axis in amd pathogenesis and reveal that the regulation of pdk activity has potential therapeutic value in this ocular disease. the results indicate that the lipoprotein profile is a traceable pattern that is worth considering for patient follow-up.